Raj Tummala
About
Raj Tummala is a scholar working on Rheumatology, Radiology, Nuclear Medicine and Imaging and Immunology.
According to data from OpenAlex, Raj Tummala has authored 79 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Rheumatology, 38 papers in Radiology, Nuclear Medicine and Imaging and 23 papers in Immunology. Recurrent topics in Raj Tummala's work include Systemic Lupus Erythematosus Research (55 papers), Monoclonal and Polyclonal Antibodies Research (38 papers) and Cytokine Signaling Pathways and Interactions (17 papers). Raj Tummala is often cited by papers focused on Systemic Lupus Erythematosus Research (55 papers), Monoclonal and Polyclonal Antibodies Research (38 papers) and Cytokine Signaling Pathways and Interactions (17 papers). Raj Tummala collaborates with scholars based in United States, Sweden and Australia. Raj Tummala's co-authors include Richard Furie, Eric F. Morand, Ian N Bruce, Yoshiya Tanaka, Anna Berglind, Philip Z. Brohawn, Lilia Pineda, Anca Askanase, Sang‐Cheol Bae and Christophe Richez and has published in prestigious journals such as New England Journal of Medicine, SHILAP Revista de lepidopterología and Gastroenterology.
In The Last Decade
Raj Tummala
73 papers receiving 2.7k citations
Hit Papers
Peers
Raj Tummala
Alessandra Bortoluzzi Italy
David Daikh United States
Stanisław Sierakowski Poland
Frederick T. Murphy United States
Anthony Sebba United States
Wendy Marder United States
Chenglong Han United States
Simon M. Helfgott United States
Andra Bălănescu Romania
S Bombardieri Italy
Citations per year, relative to Raj Tummala Raj Tummala (= 1×)
peers
Alessandra Bortoluzzi
Countries citing papers authored by Raj Tummala
Since
Specialization
Citations
This map shows the geographic impact of Raj Tummala's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Raj Tummala with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Raj Tummala more than expected).
Fields of papers citing papers by Raj Tummala
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Raj Tummala. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Raj Tummala. The network helps show where Raj Tummala may publish in the future.
Co-authorship network of co-authors of Raj Tummala
This figure shows the co-authorship network connecting the top 25 collaborators of Raj Tummala. A scholar is included among the top collaborators of Raj Tummala based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Raj Tummala. Raj Tummala is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Vollenhoven, Ronald van, Eric F. Morand, Richard Furie, et al.. (2024). LBO1 DORIS remission in patients with SLE treated with anifrolumab or placebo during the 4-year TULIP-LTE trial: post hoc analysis. SHILAP Revista de lepidopterología. A169–A170.
2.
Furie, Richard, Ian N Bruce, Kenneth Kalunian, et al.. (2024). POS0541 GLUCOCORTICOID REDUCTION AND WITHDRAWAL IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS RECEIVING LONG-TERM ANIFROLUMAB TREATMENT. Annals of the Rheumatic Diseases. 83. 958–959.
3.
Tang, Weifeng, Raj Tummala, J.O. Almquist, et al.. (2023). Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anifrolumab. Clinical Pharmacokinetics. 62(5). 655–671.
4.
Jayne, David, Brad H. Rovin, Eduardo Mysler, et al.. (2023). Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial. Lupus Science & Medicine. 10(2). e000910–e000910.
5.
Bruce, Ian N, et al.. (2023). Time to onset of clinical response to anifrolumab in patients with SLE: pooled data from the phase III TULIP-1 and TULIP-2 trials. Lupus Science & Medicine. 10(1). e000761–e000761.
6.
Morand, Eric F., Gabriel Abreu, Richard Furie, Vera Golder, & Raj Tummala. (2023). Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus. Annals of the Rheumatic Diseases. 82(5). 639–645.
7.
Vollenhoven, Ronald van, Eric F. Morand, Ian N Bruce, et al.. (2023). Targeting DORIS Remission and LLDAS in SLE: A Review. Rheumatology and Therapy. 10(6). 1459–1477.
8.
Bruce, Ian N, Ronald van Vollenhoven, Eric F. Morand, et al.. (2022). Sustained glucocorticoid tapering in the phase 3 trials of anifrolumab: apost hocanalysis of the TULIP-1 and TULIP-2 trials. Lara D. Veeken. 62(4). 1526–1534.
9.
Bruce, Ian N, Richard Furie, Eric F. Morand, et al.. (2022). Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials. Annals of the Rheumatic Diseases. 81(7). 962–969.
10.
Bruce, Ian N, Sarowar Golam, Evelyn Worthington, et al.. (2022). Indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus. Journal of Comparative Effectiveness Research. 11(10). 765–777.
11.
Strand, Vibeke, Sean O’Quinn, Richard Furie, et al.. (2022). Clinical meaningfulness of a British Isles Lupus Assessment Group-based Composite Lupus Assessment response in terms of patient-reported outcomes in moderate to severe systemic lupus erythematosus: a post-hoc analysis of the phase 3 TULIP-1 and TULIP-2 trials of anifrolumab. The Lancet Rheumatology. 4(3). e198–e207.
12.
Morand, Eric F., Richard Furie, Ian N Bruce, et al.. (2022). Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials. The Lancet Rheumatology. 4(4). e282–e292.
13.
Vital, Edward M, Joan T. Merrill, Eric F. Morand, et al.. (2022). Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials. Annals of the Rheumatic Diseases. 81(7). 951–961.
14.
White, William B., Peter R. Kowey, Ulysses Diva, Mark Sostek, & Raj Tummala. (2018). Cardiovascular Safety of the Selective μ-Opioid Receptor Antagonist Naloxegol: A Novel Therapy for Opioid-Induced Constipation. Journal of Cardiovascular Pharmacology and Therapeutics. 23(4). 309–317.
15.
Webster, Lynn R., Ulysses Diva, Raj Tummala, & Mark Sostek. (2017). Treatment with Naloxegol Versus Placebo: Pain Assessment in Patients with Noncancer Pain and Opioid‐Induced Constipation. Pain Practice. 18(4). 505–514.
16.
Möller, Hans‐Jürgen, Koen Demyttenaere, Bengt Olausson, et al.. (2015). Two Phase III randomised double-blind studies of fixed-dose TC-5214 (dexmecamylamine) adjunct to ongoing antidepressant therapy in patients with major depressive disorder and an inadequate response to prior antidepressant therapy. The World Journal of Biological Psychiatry. 16(7). 483–501.
17.
Khan, Sajjad, Dennis A. Revicki, Mariam Hassan, et al.. (2015). Assessing the Reliability and Validity of the Sheehan Irritability Scale in Patients With Major Depressive Disorder. The Journal of Clinical Psychiatry. 77(8). 1080–1086.
18.
Chun, June Young, Raj Tummala, Nagalakshmi Nadiminty, et al.. (2010). Andrographolide, an Herbal Medicine, Inhibits Interleukin-6 Expression and Suppresses Prostate Cancer Cell Growth. Genes & Cancer. 1(8). 868–876.
19.
McLaughlin, Trent P., Rezaul Karim Khandker, Denise Kruzikas, & Raj Tummala. (2006). Overlap of Anxiety and Depression in a Managed Care Population. The Journal of Clinical Psychiatry. 67(8). 1187–1193.
20.
Tummala, Raj, William E. Janssen, J. Hiemenz, et al.. (1997). High-dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with multiple myeloma and renal insufficiency. Bone Marrow Transplantation. 20(8). 653–656.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Alessandra Bortoluzzi Breakdown of academic impact, for papers by David Daikh Breakdown of academic impact, for papers by Stanisław Sierakowski Breakdown of academic impact, for papers by Frederick T. Murphy Breakdown of academic impact, for papers by Anthony Sebba Breakdown of academic impact, for papers by Wendy Marder Breakdown of academic impact, for papers by Chenglong Han Breakdown of academic impact, for papers by Simon M. Helfgott Breakdown of academic impact, for papers by Andra Bălănescu Breakdown of academic impact, for papers by S Bombardieri